Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11327001 | PMC |
| http://dx.doi.org/10.1002/ctm2.1796 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mapping the functional network of human cancer through machine learning and pan-cancer proteogenomics.
Nat Cancer
December 2024
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX, USA.
Article Synopsis
- Large-scale omics profiling has highlighted numerous somatic mutations and cancer-related proteins, making it difficult to understand their functions in cancer biology.
- The FunMap network is developed using machine learning on data from 1,194 individuals across 11 cancer types, accurately linking over 10,500 protein-coding genes and identifying important functional protein modules.
- This study positions FunMap as a valuable tool for interpreting complex cancer data, helping to predict the roles of lesser-known cancer-associated proteins and enhancing strategies for cancer treatment and research.
Integrate and conquer: pan-cancer proteogenomics uncovers cancer vulnerabilities and therapeutic opportunities.
Signal Transduct Target Ther
October 2024
Cell Biology Unit, University Medical Center Mainz, JGU-Mainz, Mainz, Germany.
Pan-cancer proteogenomic landscape of whole-genome doubling reveals putative therapeutic targets in various cancer types.
Clin Transl Med
August 2024
Department of Integrated Biomedical and Life Science, Korea University, Seoul, Republic of Korea.
Pan-cancer proteogenomics expands the landscape of therapeutic targets.
Cell
August 2024
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA; Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA. Electronic address:
Fewer than 200 proteins are targeted by cancer drugs approved by the Food and Drug Administration (FDA). We integrate Clinical Proteomic Tumor Analysis Consortium (CPTAC) proteogenomics data from 1,043 patients across 10 cancer types with additional public datasets to identify potential therapeutic targets. Pan-cancer analysis of 2,863 druggable proteins reveals a wide abundance range and identifies biological factors that affect mRNA-protein correlation.
View Article and Find Full Text PDFPan-cancer proteogenomics characterization of tumor immunity.
Cell
February 2024
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address:
Article Synopsis
- Despite the notable advancements in immunotherapy for cancer, only a small percentage (less than 20%) show lasting responses to immune checkpoint blockade, leading researchers to consider combination therapies that target multiple immune evasion strategies.
- Researchers analyzed data from over 1,000 tumors across ten cancers to identify seven distinct immune subtypes, examining their unique genomic, epigenetic, transcriptomic, and proteomic characteristics.
- By investigating kinase activities linked to these immune subtypes, the study uncovered potential therapeutic targets that could improve future immunotherapy approaches and precision medicine.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!